ATE267798T1 - Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung - Google Patents
Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzungInfo
- Publication number
- ATE267798T1 ATE267798T1 AT94909643T AT94909643T ATE267798T1 AT E267798 T1 ATE267798 T1 AT E267798T1 AT 94909643 T AT94909643 T AT 94909643T AT 94909643 T AT94909643 T AT 94909643T AT E267798 T1 ATE267798 T1 AT E267798T1
- Authority
- AT
- Austria
- Prior art keywords
- codrug
- targeted
- active
- release
- combined
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
- C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/0026—Oxygen-containing hetero ring cyclic ketals
- C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18746294A | 1994-01-28 | 1994-01-28 | |
PCT/US1994/001659 WO1995020567A1 (en) | 1994-01-28 | 1994-02-17 | Codrugs as a method of controlled drug delivery |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE267798T1 true ATE267798T1 (de) | 2004-06-15 |
Family
ID=22689099
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT94909643T ATE267798T1 (de) | 1994-01-28 | 1994-02-17 | Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0740650B1 (de) |
JP (1) | JP4039683B2 (de) |
AT (1) | ATE267798T1 (de) |
AU (1) | AU705226B2 (de) |
CA (1) | CA2182228C (de) |
DE (1) | DE69433818T2 (de) |
DK (1) | DK0740650T3 (de) |
ES (1) | ES2222455T3 (de) |
PT (1) | PT740650E (de) |
WO (1) | WO1995020567A1 (de) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207673B1 (en) | 1997-03-12 | 2001-03-27 | The University Of North Carolina At Chapel Hill | Covalent conjugates of topoisomerase I and topoisomerase II inhibitors |
AU740264C (en) * | 1997-09-11 | 2002-06-06 | Commonwealth Scientific And Industrial Research Organisation | Antiviral agents |
JPH11171768A (ja) * | 1997-10-15 | 1999-06-29 | Taisho Pharmaceut Co Ltd | 消炎鎮痛外用剤 |
SE9803761D0 (sv) * | 1998-11-04 | 1998-11-04 | Synphora Ab | Method to avoid increased iridial pigmentation during prostaglandin treatment |
US6762182B1 (en) | 1999-01-07 | 2004-07-13 | Vanderbilt University | Converting cox inhibition compounds that are not COX-2 selective inhibitors to derivatives that are COX-2 selective inhibitors |
US6207700B1 (en) | 1999-01-07 | 2001-03-27 | Vanderbilt University | Amide derivatives for antiangiogenic and/or antitumorigenic use |
US6306890B1 (en) | 1999-08-30 | 2001-10-23 | Vanderbilt University | Esters derived from indolealkanols and novel amides derived from indolealkylamides that are selective COX-2 inhibitors |
US6375972B1 (en) | 2000-04-26 | 2002-04-23 | Control Delivery Systems, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
US6624317B1 (en) | 2000-09-25 | 2003-09-23 | The University Of North Carolina At Chapel Hill | Taxoid conjugates as antimitotic and antitumor agents |
FR2818908B1 (fr) * | 2000-12-29 | 2004-04-02 | Dospharma | Utilisation en tant que medicament d'un compose restituant in vivo des principes actifs |
EP2283845A1 (de) * | 2001-04-26 | 2011-02-16 | pSivida Inc. | Retardformulierung mit konjugierten Wirkstoffen |
IN2014DN10834A (de) * | 2001-09-17 | 2015-09-04 | Psivida Inc | |
US20030203030A1 (en) * | 2002-01-18 | 2003-10-30 | Control Delivery Systems, Inc. | Polymeric gel delivery system for pharmaceuticals |
EP1485082A4 (de) * | 2002-02-19 | 2009-12-30 | Xenoport Inc | Syntheseverfahren für prodrugs von 1-acyl-alkyl derivaten und ihre zusammensetzungen |
US20050009798A1 (en) | 2002-02-20 | 2005-01-13 | Sepracor Inc. | Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists |
WO2003070745A2 (en) | 2002-02-20 | 2003-08-28 | Sepracor Inc. | Carbonate and carbamate modified forms of glucocorticoids |
CA2484632C (en) * | 2002-05-07 | 2012-12-11 | Control Delivery Systems, Inc. | Processes for forming a drug delivery device |
US8871241B2 (en) | 2002-05-07 | 2014-10-28 | Psivida Us, Inc. | Injectable sustained release delivery devices |
US7101912B2 (en) | 2002-12-06 | 2006-09-05 | Xenoport, Inc. | Carbidopa prodrugs and derivatives, and compositions and uses thereof |
WO2004112838A2 (en) * | 2003-05-21 | 2004-12-29 | Control Delivery Systems, Inc. | Codrugs of diclofenac |
FR2867189A1 (fr) * | 2004-03-08 | 2005-09-09 | Ludovic Bourre | Nouveaux composes medicamenteux destines au traitement des pathologies dependantes de l'activite proteine kinase |
CA2562783A1 (en) | 2004-04-26 | 2005-12-01 | Vanderbilt University | Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity |
CA2467321A1 (en) | 2004-05-14 | 2005-11-14 | Paul J. Santerre | Polymeric coupling agents and pharmaceutically-active polymers made therefrom |
EP1868653A2 (de) * | 2005-04-12 | 2007-12-26 | PSivida Inc. | Komedikamente von hmgcoa-reduktasehemmern und ihre verwendung |
JP2009503075A (ja) * | 2005-08-01 | 2009-01-29 | シヴィダ・インコーポレイテッド | HMGCoA還元酵素インヒビターコドラッグ及びその使用 |
AU2007227202B2 (en) | 2006-03-21 | 2013-08-22 | Amylin Pharmaceuticals, Llc | Peptide-peptidase inhibitor conjugates and methods of using same |
CA2657691A1 (en) | 2006-06-19 | 2007-12-27 | Vanderbilt University | Methods and compositions for diagnostic and therapeutic targeting of cox-2 |
US8598314B2 (en) | 2007-09-27 | 2013-12-03 | Amylin Pharmaceuticals, Llc | Peptide-peptidase-inhibitor conjugates and methods of making and using same |
WO2010058417A1 (en) * | 2008-11-19 | 2010-05-27 | Council Of Scientific & Industrial Research | Isoxazole/isoxazoline/combretastatin linked dihydroquinazolinone hybrids as potential anticancer agents and process for the preparation thereof |
CN102803203B (zh) | 2009-05-12 | 2016-05-11 | 罗马克实验室有限公司 | 卤代烷基杂芳基苯甲酰胺化合物 |
CN108042535A (zh) | 2009-06-26 | 2018-05-18 | 罗马克实验室有限公司 | 用于治疗流感的化合物和方法 |
EP2651864B1 (de) | 2010-12-17 | 2016-07-13 | Neonc Technologies Inc. | Verfahren und vorrichtungen zur verwendung von isoperillylalkohol |
WO2013059245A1 (en) | 2011-10-17 | 2013-04-25 | Vanderbilt University | Indomethacin analogs for the treatment of castrate-resistant prostate cancer |
KR20150126032A (ko) | 2013-03-08 | 2015-11-10 | 알러간, 인코포레이티드 | 스테로이드 약물과 직접 결합된 항생제 컨쥬게이트 |
EP2964268A1 (de) | 2013-03-08 | 2016-01-13 | Allergan, Inc. | Antibiotische konjugate |
CN103588713B (zh) * | 2013-06-07 | 2014-09-17 | 潍坊博创国际生物医药研究院 | 多靶点型乌苯美司前药衍生物及其制备方法和用途 |
WO2015027018A1 (en) * | 2013-08-21 | 2015-02-26 | Senseonics, Incorporated | Drug elution for in vivo protection of bio-sensing analytes |
JP2021512852A (ja) | 2018-02-02 | 2021-05-20 | リップル セラピューティクス コーポレーション | ステロイド二量体を含むガラス製剤およびその使用 |
JP2022539523A (ja) * | 2019-06-24 | 2022-09-12 | ダイヴァース バイオテック, インコーポレイテッド | カンナビノイド抱合分子 |
US20220288277A1 (en) * | 2019-07-10 | 2022-09-15 | Ripple Therapeutics Corporation | Surface coatings and implantable devices comprising dimeric steroid prodrugs, and uses thereof |
EP4003362A4 (de) * | 2019-07-25 | 2023-11-15 | Ripple Therapeutics Corporation | Artikel mit steroiddimeren und ihre verwendung zur abgabe therapeutischer mittel |
EP4146664A2 (de) | 2020-05-01 | 2023-03-15 | Ripple Therapeutics Corporation | Heterodimerzusammensetzungen und verfahren zur behandlung von augenerkrankungen |
CN113943312A (zh) * | 2020-07-17 | 2022-01-18 | 轶诺(浙江)药业有限公司 | 一类肠道裂解型共药及其制备和用途 |
US11883499B2 (en) | 2022-02-01 | 2024-01-30 | Akos Biosciences, Inc. | Cannabinoid conjugate molecules |
US11660348B1 (en) | 2022-02-01 | 2023-05-30 | Akos Biosciences, Inc. | Cannabinoid conjugate molecules |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8907617D0 (en) * | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
AU649275B2 (en) * | 1990-11-06 | 1994-05-19 | Bristol-Myers Squibb Company | Prodrugs for beta-lactamase and uses thereof |
US5157151A (en) * | 1990-12-18 | 1992-10-20 | Isaac Angres | Salts of 1-adamantamine and formulations thereof |
GB2278843A (en) * | 1993-06-07 | 1994-12-14 | British Tech Group | Anti-cancer compounds |
-
1994
- 1994-02-17 CA CA002182228A patent/CA2182228C/en not_active Expired - Lifetime
- 1994-02-17 AT AT94909643T patent/ATE267798T1/de active
- 1994-02-17 WO PCT/US1994/001659 patent/WO1995020567A1/en active IP Right Grant
- 1994-02-17 DK DK94909643T patent/DK0740650T3/da active
- 1994-02-17 AU AU62545/94A patent/AU705226B2/en not_active Expired
- 1994-02-17 JP JP52002395A patent/JP4039683B2/ja not_active Expired - Lifetime
- 1994-02-17 ES ES94909643T patent/ES2222455T3/es not_active Expired - Lifetime
- 1994-02-17 EP EP94909643A patent/EP0740650B1/de not_active Expired - Lifetime
- 1994-02-17 PT PT94909643T patent/PT740650E/pt unknown
- 1994-02-17 DE DE69433818T patent/DE69433818T2/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE69433818T2 (de) | 2005-06-16 |
DK0740650T3 (da) | 2004-09-27 |
EP0740650B1 (de) | 2004-05-26 |
ES2222455T3 (es) | 2005-02-01 |
PT740650E (pt) | 2004-10-29 |
EP0740650A1 (de) | 1996-11-06 |
AU705226B2 (en) | 1999-05-20 |
CA2182228C (en) | 2008-09-16 |
JP4039683B2 (ja) | 2008-01-30 |
JPH09509151A (ja) | 1997-09-16 |
WO1995020567A1 (en) | 1995-08-03 |
AU6254594A (en) | 1995-08-15 |
DE69433818D1 (de) | 2004-07-01 |
CA2182228A1 (en) | 1995-08-03 |
EP0740650A4 (de) | 2000-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE267798T1 (de) | Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung | |
ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
ATE399553T1 (de) | Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen | |
BR0108977A (pt) | Compostos azacìclicos para uso no tratamento de doenças relaciondas com serotonina | |
MXPA03010402A (es) | Derivados de 4-amino-5-fenil-7-ciclobutil-pirrolo (2,3-d) pirimidina. | |
BR0008590A (pt) | Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto | |
DE60041976D1 (de) | Phenoxycarbonsäureverbindungen und zusammensetzungen zur verabreichung aktiver wirkstoffe | |
DE69736745D1 (de) | Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe | |
DE69529054T2 (de) | System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung | |
DE69232263T2 (de) | Radikalfänger ("spin traps") zur behandlung von mit oxidation von lipiden und proteinen verbundenen erkrankungen | |
ATE396967T1 (de) | (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten | |
DE60033649D1 (de) | Verbindungen und therapeutische methoden | |
IS6558A (is) | Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni | |
ATE336997T1 (de) | Fulvinsäure und dessen verwendung zur behandlung von diversen krankheitszuständen | |
BR9813318A (pt) | Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário | |
DE60137146D1 (de) | Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten | |
EA199800717A1 (ru) | Способ лечения заболеваний млекопитающих и цвиттерионная композиция | |
DE69939075D1 (de) | Pharmazeutische Zusammenstellung zur Vorbeugung und Behandlung von mit Zellkrankheiten des Augenhintergrundes zusammenhängenden Krankheiten | |
ATE316379T1 (de) | Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen | |
ATE226065T1 (de) | Feste instant-release-darreichungsformen und verfahren zu ihrer herstellung | |
DE69803670T2 (de) | Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung | |
HUP9903679A2 (hu) | Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására | |
ATE106732T1 (de) | Arzneimittelzubereitung, enthaltend stigmasta-4- en-3-on sowie deren verwendung. | |
ATE306278T1 (de) | Behandlung von knochenleiden mit adrenomedullin | |
DE60202299D1 (de) | Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0740650 Country of ref document: EP |